DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management (2019)
- Authors:
- Autor USP: NOUSHMEHR, HOUTAN - FMRP
- Unidade: FMRP
- DOI: 10.1093/neuonc/noz061
- Subjects: MENINGIOMA; METILAÇÃO; DNA; RADIOTERAPIA; ESTUDOS DE VALIDAÇÃO
- Keywords: Methylation; Meningioma; Nomogram; Predictor; Recurrence
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Neuro-Oncology
- ISSN: 1522-8517
- Volume/Número/Paginação/Ano: v. 21, n. 7, p. 901-910, 2019
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: public-domain
-
ABNT
NASSIRI, Farshad et al. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncology, v. 21, n. 7, p. 901-910, 2019Tradução . . Disponível em: https://doi.org/10.1093/neuonc/noz061. Acesso em: 27 dez. 2025. -
APA
Nassiri, F., Mamatjan, Y., Suppiah, S., Badhiwala, J. H., Mansouri, S., Karimi, S., et al. (2019). DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncology, 21( 7), 901-910. doi:10.1093/neuonc/noz061 -
NLM
Nassiri F, Mamatjan Y, Suppiah S, Badhiwala JH, Mansouri S, Karimi S, Saarela O, Poisson L, Gepfner-Tuma I, Schittenhelm J, Noushmehr H. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management [Internet]. Neuro-Oncology. 2019 ; 21( 7): 901-910.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1093/neuonc/noz061 -
Vancouver
Nassiri F, Mamatjan Y, Suppiah S, Badhiwala JH, Mansouri S, Karimi S, Saarela O, Poisson L, Gepfner-Tuma I, Schittenhelm J, Noushmehr H. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management [Internet]. Neuro-Oncology. 2019 ; 21( 7): 901-910.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1093/neuonc/noz061 - Integrative analysis identifies functional prostate cancer risk SNPs in genomic regulatory regions defined as enhancers
- Genome-wide fingerprinting of regulatory chromatin to evaluate the tissue specific origins of high-grade serous ovarian cancer
- Epigenomic (DNA methylation and expression) signatures define subsets of both IDHmut and IDHwt glioma with distinct clinical outcomes
- Molecular patterns at regulatory elements diferentially methylated in glioma
- Clinical data that matters: a distillation of neuro-oncology clinical trial inclusion criteria using machine learning
- Genomic landscape of idh-mutant primary glioblastomas shows distinct clinical and molecular features and that CDKN2A should be supplemented with MGMTp and G-CIMP for precise prognostication
- Tumor-myeloid cell interactions are dynamic and influence the evolutionary trajectory of adult diffuse glioma
- DNA methylation signature associated with risk of recurrence in papillary thyroid carcinoma
- SpidermiR: an R/Bioconductor package for integrative analysis with miRNA data
- Epigenomic glioma subtype evaluation across 31 tumor types
Informações sobre o DOI: 10.1093/neuonc/noz061 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
